Cellular Cause of Disease
Cystic fibrosis condition is caused through genetics on the basis of inheritance. Cystic fibrosis occurs through a series of mutations that occur in a gene known as cystic fibrosis transmembrane conductance regulator (CFTR) (Cutting, 2015). The CFTR proteins are also present in very sensitive organs in the body such as the heart and the overall immune system of a person. Consequently, Cystic fibrosis is also conceptualized as an autosomal recessive illness that comes with the combination of sweat producing gland and mucus. Cystic fibrosis also affects the walls of the lungs (Shannon, 2016). The fact that CFTR allows the passage of chloride through the cells that produce mucus denotes a potential cause for Cystic fibrosis that results into thick and sticky mucus that obstruct the pathways and the walls of the lungs. A lung infection called pseudomonas is a sign and indication of Cystic fibrosis.
Disease- Basic information
The feeling of dehydration, heart stroke and fatigue, and arrhymias denotes the possible signs of a Cystic fibrosis infection. The effects on sensitive organs of the body such as the lungs and the heart come out as the major adverse effects of Cystic fibrosis infection. Cysti fibrosis infection is very serious based on the fact that it leads to a 90% death of infected patients (De Boeck & Amaral, 2016). The CFTR gene regulate chloride channel within the body of patients, and this outlines the concern of dehydration. Cystic fibrosis causes lung infection as a result of the sticky mucus obstructing the pathways within the trachea. Cystic fibrosis is inherited.
Delegate your assignment to our experts and they will do the rest.
Disease Treatment and Research
The treatment of Cystic fibrosis entails cleaning the respiratory system in a bid to control the lung infection. In most instances, antibiotics are prescribed to control lung infection. Antibiotics prescribed for the disease includes azithromycin, tobramycin and levofloxacin. The sensitivity of pattern of an antibiotic outlines its recommendation for the treatment of Cystic fibrosis. The control of airway inflammation that is called the NSAIDs a preferred mode of cleaning the respiratory system (Fajac & De Boeck, 2017). The reduction of viscoelasticity that entails the removal of thick sticky mucus is also a procedure for treating cystic fibrosis. The GIT that entails the prevention or rather the treatment of intestinal blockages is recommended for the treatment of cystic fibrosis disease. In this connection, the oral polyethylene that includes the mixture of glycol 3350 is recommended for a patient for the treatment of cystic fibrosis (Cutting, 2015). On the same note, the pancreatic enzyme replacement therapy that is conceptualized as PERT is a valid treatment specification for a patient infected with cystic fibrosis. The future research dwells on the therapeutic targets that focuses on building both structural and functional abnormalities that are caused based on the interference of the CFTR proteins in the body of a patient. Besides, a research needs to be conducted on the improvement of symptomatic.
Summary of Findings
Cystic fibrosis is a confirmed autosomal recessive disorder. The mutations that emerge as a result of the presence of thick sticky mucus cause the abnormality of chloride channels within the body of a patient. The respiratory system and the GIT are the major targets that are adversely affected through Cystic fibrosis infection. However, sensitive body organs such as the heart and the pancreas are also affected. Cystic fibrosis infection as claimed several lives with a 90% chance of infected patients die if not treated (Cutting, 2015). Nutritional support plays a significant role in the management, control and treatment of cystic fibrosis. On the same note, drug therapy and physiotherapy are considered as the significant steps towards a successful treatment of cystic fibrosis. The focus on symptomatic improvement comes as a requisite approach to reducing the risk of getting cystic fibrosis infection.
References
Cutting, G. R. (2015). Cystic fibrosis genetics: from molecular understanding to clinical application. Nature Reviews Genetics , 16 (1), 45-56.
De Boeck, K., & Amaral, M. D. (2016). Progress in therapies for cystic fibrosis. The Lancet Respiratory Medicine , 4 (8), 662-674.
Fajac, I., & De Boeck, K. (2017). New horizons for cystic fibrosis treatment. Pharmacology & therapeutics , 170 , 205-211.
Shannon. S. (2016). The Cellular Mechanism of CS: The Basics. Cystic Fibrosis News Today/ Retrieved from
https://systicfibrosisnewstoday.com/2015/cellularmechanism-of-cf-the-basics/
